/
ARQT
$26.76-$0.24 (-0.89%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$3.4B
125M shares
52-week range
$13.06 – $31.77
73% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-0.53
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $3.7M | $59.6M | $196.5M | $376.1M |
| Cost of revenue | $0 | $195.0K | $455.0K | $763.0K | $754.0K | $5.0M | $19.1M | $36.7M |
| Gross profit | $0 | −$195.0K | −$455.0K | −$763.0K | $2.9M | $54.6M | $177.4M | $339.4M |
| Gross margin | — | — | — | — | 79.5% | 91.6% | 90.3% | 90.2% |
| R&D | $17.9M | $36.5M | $115.3M | $145.6M | $182.4M | $110.6M | $76.4M | $77.1M |
| Operating income | −$19.7M | −$43.1M | −$136.6M | −$206.5M | −$301.6M | −$241.1M | −$128.4M | −$12.2M |
| EBITDA | $480.0K | −$41.8M | −$135.2M | −$205.6M | −$294.6M | −$227.4M | −$109.6M | $2.5M |
| Net income | −$19.3M | −$42.0M | −$135.7M | −$206.4M | −$311.5M | −$262.1M | −$140.0M | −$16.1M |
| Net margin | — | — | — | — | -8449.8% | -439.8% | -71.3% | -4.3% |
| EPS (diluted) | -0.53 | -1.10 | -3.80 | -4.17 | -5.66 | -3.78 | -1.16 | -0.13 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $497M | $0.20 | $-0.07–$0.38 | 4 |
| 2027 | $646M | $1.07 | $0.88–$1.39 | 5 |
| 2028 | $783M | $1.84 | $1.13–$2.76 | 6 |
| 2029 | $920M | $2.48 | $2.40–$2.60 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Arcutis Biotherapeutics, Inc. Common Stock
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
www.arcutis.com- Employees
- 354
- IPO / List date
- Jan 31, 2020
- HQ
- WESTLAKE VILLAGE, CA
Held by traders on TradeandTell
No one on the platform currently holds ARQT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 440,999 | $10.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ARQT yet.
